Filing Flows › Xenon Pharmaceuticals (XENE) › Takeover & LBO
Is Xenon Pharmaceuticals (XENE) a takeover target?
A leveraged buyout does not work for Xenon Pharmaceuticals on its latest figures: it has no positive EBITDA to borrow against (−$439M over the last 12 months).
Why a leveraged buyout does not fit
A leveraged buyout is paid for mostly with debt that the company's own cash flow repays. Xenon Pharmaceuticals' EBITDA over the last 12 months was −$439M, so there is nothing to lend against and nothing to repay a loan with: a buyer would have to pay almost entirely with its own money. That is the kind of deal another company — a strategic buyer that wants the products, the pipeline or the technology — makes, not a private-equity fund. The model therefore gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Xenon Pharmaceuticals would cost about $49.19 a share, $4.9B for all its shares.
| Premium | % | Price a share | All shares |
|---|---|---|---|
| Low end (a quarter of deals paid less) | 22% | $44.46 | $4.4B |
| Median | 35% | $49.19 | $4.9B |
| High end (a quarter paid more) | 45% | $52.84 | $5.3B |
Xenon Pharmaceuticals' latest quarter
Xenon Pharmaceuticals, Q1 2025: revenue $7.5M, operating margin -969.8%, net loss $65.0M, operating cash flow −$61.7M. The chart follows the revenue to costs, profit and cash.
Questions
Is Xenon Pharmaceuticals being acquired?
No headline, 8-K or 13D about a sale is on file in the last year.
Could private equity buy Xenon Pharmaceuticals?
A leveraged buyout does not work for Xenon Pharmaceuticals on its latest figures: it has no positive EBITDA to borrow against (−$439M over the last 12 months). With no cash flow to repay a loan, a buyer would pay almost entirely with its own money: a deal for another company (a strategic buyer), not for a private-equity fund.
What would a takeover of Xenon Pharmaceuticals cost?
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Xenon Pharmaceuticals would cost about $49.19 a share, $4.9B for all its shares.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.